Original Article

PGHN

Safety of a New Synbiotic Starter Formula

Yvan Vandenplas, Antonis Analitis^{*}, Chara Tziouvara[†], Athina Kountzoglou[†], Anastasia Drakou[†], Manos Tsouvalas[†], Antigoni Mavroudi[†], Ioannis Xinias[†]

Department of Pediatrics, Universitair Ziekenhuis Brussel, Vrije Universiteit Brussel, Brussels, Belgium, *Department of Hygiene, Epidemiology and Medical Statistics, Faculty of Medicine, National and Kapodistrian University of Athens, Athens, [†]3rd Pediatric Department, Hippocration Hospital, Thessaloniki, Greece

Purpose: Breastfeeding is the best way to feed all infants, but not all infants can be (exclusively) breastfed. Cow's milk based infant formula is the second choice infant feeding.

Methods: The safety of a new synbiotic infant formula, supplemented with *Bifidobacterium lactis* and fructo-oligosaccharides, with lactose and a whey/casein 60/40 protein ratio was tested in 280 infants during 3 months. **Results:** The median age of the infants at inclusion was 0.89 months. Weight evolution was in accordance with the World Health Organization growth charts for exclusive breastfed infants. The evolution of all anthropometric parameters (weight-for-length z score and body mass index-for-age z score) was within the normal range. The incidence of functional constipation (3.2%), daily regurgitation (10.9%), infantile crying and colic (10.5%) were all significantly lower than the reported median prevalence for a similar age according to literature (median value of 7.8% for functional constipation, 26.7% for regurgitation, 17.7% for infantile colic).

Conclusion: The new synbiotic infant starter formula was safe, resulted in normal growth and was well tolerated. Functional gastro-intestinal manifestations (functional constipation, regurgitation and colic) were significantly lower than reported in literature. Synbiotics (*Bifidobacterium lactis* and fructo-oligosaccharides) in cow's milk based infant formula bring the second choice infant feeding, formula, closer to the golden standard, exclusive breastfeeding.

Key Words: Functional gastrointestinal disorder, Growth, Infant formula, Prebiotics, Probiotics, Synbiotics

INTRODUCTION

Human milk is the preferred feeding for all newborn infants and provides all nutrients needed to support growth and development during early life. Human milk contains bioactive components such as prebiotic oligosaccharides and probiotics that have a positive impact on gut microbial colonization, immune maturation and overall health [1-3]. Because human-milk feeding is not always possible, infant formula has been developed as a replacement. The maturation of the gastro-intestinal (GI) tract func-

Received : March 13, 2017, Revised : April 6, 2017, Accepted : April 24, 2017

Corresponding author: Yvan Vandenplas, Department of Pediatrics, Universitair Ziekenhuis Brussel, Vrije Universiteit Brussel, Laarbeeklaan 101, 1090 Brussels, Belgium. Tel: +32-2-477-57-94, Fax: +32-2-477-57-80, E-mail: Yvan.Vandenplas@uzbrussel.be

Copyright © 2017 by The Korean Society of Pediatric Gastroenterology, Hepatology and Nutrition

This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

tions is influenced by the dynamic process of the development of the intestinal microbiota, which is considered crucial for a healthy infant [4]. One of the major differences between human milk and cow's milk based infant formula is the almost absence of prebiotic oligosaccharides in cow's milk, resulting in the development of a different GI microbiota, if not supplemented [5]. Breastfed infants typically have a microbiota dominated by bifidobacteria, whereas non-prebiotic supplemented formula-fed infants have a more diverse microbiota [6]. Probiotic bacteria are present in fresh human milk, but absent in unuspplemented infant formula [7]. Fructo-oligosaacharides (FOS), when added to infant formula, have a bifidogenic effect [5,8]. The addition of Bifidobacterium lactis to infant formula results in a normal growth in healthy infants, and a better growth in HIV-positive infants [9,10]. The Committee on Nutrition of the European Society of Paediatrc Gastroenterology, Hepatology and Nutrition (ES-PGHAN) reported that the available scientific data suggest that the administration of currently evaluated probiotic- and/or prebiotic-supplemented formula to healthy infants does not raise safety concerns with regard to growth and adverse effects [11]. The safety and clinical effects of one product should not be extrapolated to other products [11].

The safety and tolerance of a new synbiotic infant formula, containing FOS and *B. lactis*, was evaluated with daily weight gain as primary outcome parameter, and in addition weight-for-length and body mass index (BMI)-for-age z score, length gain, head circumference, and the frequency of functional GI symptoms (regurgitation, defeceation) and crying were monitored.

MATERIALS AND METHODS

Subjects were healthy infants recruited by general paediatricians from i) mothers who had decided to not breastfeed, ii) mother who had decided autonomous to discontinue breastfeeding, iii) mothers who were feeding a different starter formula because they had already choosen to not breastfeed and accepted the switch to the study formula. The participating infants represent an unselected population of healthy infants followed by general paedaitricians.

Inclusion criteria were gestational age between 37 weeks and 42 weeks with a birth weight between 2.5 and 4.5 kg and a postnatal age of less than 3 months. Parents needed to be older than 18 years. Infants were excluded if they were considered to have a congenital condition or any symptoms or manifestations suggesting chronic disease. An approval of the study protocol by the independent Ethical Review Board of the Aristoteleion University of Thesalonica was obtained (IRB no. 347/20-12-2016). Written informed consent was obtained from at least one parent, according to the requirements in Greece.

Eighty general paediatrians from Greece participated in the study. The mean number of included infants per participating doctor was four (range 1 to 12 [min-max]).

This study was a prospective, open trial over a period of three months intervention with the study formula in 280 infants, whose parents intended to feed their infants (partially) formula and agreed to feed the new synbiotic formula. The characteristics of the infants are listed in Table 1. Parents were informed by the paediatrician about the novel aspects of the study

Characteristic	Value
Age at entry (wk)	3.8 ± 3.6
Boy/girl	144 (51.4)/136 (48.6)
lst born (yes/no)	76 (27.1)/204 (72.9)
Delivery (vaginal/C section)	165 (58.9)/115 (41.1)
NICU (no/yes)	271 (96.8)/9 (3.2)
Medication before entry (no/yes)	274 (97.9)/6 (2.1)
Feeding before entry study	
Exclusive breastfeeding	80 (28.6)
Other starter formula	46 (16.4)
Mixed breastfeeding	79 (28.2)
Study formula from birth	75 (26.8)
Feeding during study period	
Study formula exclusive	227 (81.1)
Mixed breastfeeding and	53 (18.9)
study formula	

Values are presented as mean±standard deviation or number (%). C section: caesarean section, NICU: neonatal intensive care unit.

formula. Baseline measurements were collected at inclusion. An appropriate volume for one month of the study formula with written preparation instructions was provided to the parents, who were given the normal recommendations for infant feeding. The study formula was powder infant formula providing complete nutritional support for infants in the first six months of life. The detailed composition, which is in accordance with the Commission Directive 2006/141/EC, is listed in Table 2. Specific for the study formula is the addition of FOS (0.35 g/100 mL) and *B. lactis* (10⁷ cfu/g powder). Formula was prepared with boiled water which was cooled down

Table 2. Composition of Study Formula

Per 100	σ	mL	kcal
161 100	g	IIIL	KCdl
Energy (kJ)	2,124	287	418
(kcal)	508	69	100
Fat (g)	26.2	3.5	5.2
Of which saturated fatty acids (g)	8.6	1.2	1.7
Of which MUFA (g)	10.2	1.4	2.0
Of which PUFA (g)	6.0	0.8	1.2
Of which linoleic acid (g)	5.3	0.72	1.05
Of which α -linolenic acid (mg)	543.7	73	107
Of which AA (mg)	88.8	12.0	17.5
Of which DHA (mg)	51.9	7.0	10.2
Carbohydrates (g)	55.7	7.5	11.0
Of which sugars (g)	47.1	6.4	9.3
Of which lactose (g)	45.3	6.1	8.9
Fibre (g)	2.6	0.35	0.51
Of which fructo-oligosaccharides (g) 2.6	0.35	0.51
Protein (g)	11.1	1.5	2.2
Of which whey protein (g)	6.8	0.9	1.3
Of which casein (g)	4.4	0.6	0.9
Vitamins			
A (μg)	503	68	99
D3 (µg)	7.1	0.96	1.40
E (mg)	6.8	0.92	1.34
K1 (μg)	49	6.6	9.6
C (mg)	94	12.7	18.5
B1 (μg)	471	64	93
B2 (mg)	1.3	0.18	0.26
B6 (μg)	469	63	92
B12 (µg)	1.7	0.23	0.33
Niacin (mg)	4.4	0.59	0.87
Folic acid (μg)	99	13.4	19.5
Pantothenic acid (mg)	5	0.68	0.98

MUFA: mono unsaturated fatty acids, PUFA: poly unsaturated fatty acids, AA: arachidonic acid, DHA: docosahexaenoic acid.

to 40°C at the time of reconstitution. The probiotic is in the formula in an inactive state until reconstitution. After preparation the formula was at body temperature. Infants were fed at libitum. During the three months intervention period infants were either partially breast and study formula fed with a minimal daily intake of 60 mL of the study formula, or fed exclusively with the study formula starting on the day of enrolment during three months. Four visits were scheduled: at inclusion, and after 1, 2, and 3 months. Parents were provided with diaries to record formula acceptance, regurgitation (frequency, volume), defaecation (frequency, composition), crying during the past week. The paediatrician collected the weekly feedback at the end of every month, and filled in the questionnaire according to the information provided by the parents. At each visit, investigators collected anthropometric measures, reviewed compliance (evaluation of the diaries and returned study product) and assessed regurgitation, defaecation and crying according to the information provided in the diaries. Parents were asked to categorize the composition of the stools as liquid, creamy, jelly and hard. Regarding regurgitation, the options for frequency were: absent, occasionally $(\leq 1/day)$, frequent (daily). The options for the regurgitated volume were: no, insignificant or significant volume. Regarding crying, data were collected regarding frequency (no, < 1/day, daily), timing (day/night), unsoothable crying or not, duration (3 hours or more per day). Pediatricians were asked to score their overall satisfaction of the study formula, on Likert scale 0 (no satisfaction) to 10 (complete satisfaction).

All data were collected and analysed by an independent statistician. The primary outcome was weight gain per day from study entry during 3 months. The secondary outcomes were weight-forlength and BMI-for-age z score, length, head circumference and information on regurgitation, defecation and crying.

At each visit, the weight of each infant was recorded by weighing them twice naked, on calibrated electronic scales, and if deviation was > 100 g, an additional measurement was performed. The mean supine length was measured twice using a standard measuring board, and in case of a deviation of >5 mm an additional measurement was performed. A non-stretchable slotted insertion tape was used to measure head circumference. In case a third meas-

urement was required, the mean of the two measures closest together was used as outcome.

The weight gain was plotted against the World Health Organization (WHO) Child Growth Standards of breastfed infants. The evolution of the weight-

Table 3. Regurgitation Characteristics (Frequencies, %) over Study Period

	After 1 month	After 2 months	After 3 months	<i>p</i> -value*
Regurgitation frequency				< 0.001
No	113 (40.4)	170 (60.7)	226 (80.7)	
<1/day	138 (49.3)	102 (36.4)	52 (18.6)	
Daily	29 (10.4)	8 (2.9)	2 (0.7)	
Total	280 (100.0)	280 (100.0)	280 (100.0)	
Regurgitation volume				< 0.001
No	123 (43.9)	176 (62.9)	226 (80.7)	
Insignificant	153 (54.6)	102 (36.4)	53 (18.9)	
Significant	4 (1.4)	2 (0.7)	1 (0.4)	
Total	280 (100.0)	280 (100.0)	280 (100.0)	

Values are presented as number (%).

*Friedman.

Table 4. Crying Characteristics (Frequencies, %) over Study Period

	After 1 month	After 2 months	After 3 months	p-value*
Crying, unsoothable				
No	240 (85.7)	266 (95.0)	278 (99.3)	< 0.001 ⁺
Yes	40 (14.3)	14 (5.0)	2 (0.7)	< 0.001 [†]
Total	280 (100.0)	280 (100.0)	280 (100.0)	$0.004^{\$}$
Crying, duration				
No	254 (90.7)	274 (97.9)	280 (100.0)	< 0.001
>3 h	26 (9.3)	6 (2.1)	0 (0)	< 0.001
Total	280 (100.0)	280 (100.0)	280 (100.0)	0.031
Crying timing-day				
No	262 (93.6)	265 (94.6)	278 (99.3)	0.438
Yes	18 (6.4)	15 (5.4)	2 (0.7)	< 0.001
Total	280 (100.0)	280 (100.0)	280 (100.0)	0.001
Crying timing-night				
No	205 (73.2)	234 (83.6)	269 (96.1)	< 0.001
Yes	75 (26.8)	46 (16.4)	11 (3.9)	< 0.001
Total	280 (100.0)	280 (100.0)	280 (100.0)	< 0.001
Crying frequency-everyday				
No	234 (83.6)	270 (96.4)	278 (99.3)	< 0.001
Yes	46 (16.4)	10 (3.6)	2 (0.7)	< 0.001
Total	280 (100.0)	280 (100.0)	280 (100.0)	0.021
Crying frequency-occasionally				
No	164 (58.6)	183 (65.4)	241 (86.1)	0.037
Yes	116 (41.4)	97 (34.6)	39 (13.9)	< 0.001
Total	280 (100.0)	280 (100.0)	280 (100.0)	< 0.001

Values are presented as number (%).

*Mc Nemar, [†]after 1 month vs. 2 months, [†]after 1 month vs. 3 months, [§]after 2 months vs. 3 months.

for-length and BMI-for-age z scores were calculated.

Statistical analysis

The weight gain was plotted against the WHO Child Growth Standards of breastfed infants (31). The evolution of the weight-for-length and BMI-for-age z scores were calculated. Changes over study period in continuous variables were evaluated using repeated measures ANOVA. Friedman test was used in case of violation of normality assumption and for ordered variables. Categorical variables were analysed by using chi-square tests (Fisher's exact tests in case that sparse cells occurred) or McNemar's test. All tests were two-sided in $\alpha = 0.05$ level of statistical significance. Statistical analysis was performed using STATA ver. 10 (2007; Stata Co., College Station, TX, USA).

RESULTS

Compliance to the protocol was dependent on the parameters, and ranged from 100% over the three month study period to 45.4% (127/280) due to the collected information on duration of crying at enrolment (Table 3-7). General satisfaction, scored by the pediatricians on a 0-10 score was 9.3 (standard deviation 0.8). There was no infant in whom the study formula had to be stopped and switched to a different formula.

Weight gain of the infants was plotted on the WHO-growth charts for exclusively breast fed infants (Fig. 1 and 2). The median (P50) weight of the girls was at inclusion close to the P50 of the

WHO-chart and the evolution over the three month intervention period was parallel to the P50 WHO growth chart (Fig. 1). The median weight of the boys at inclusion was on the P25 of the WHO growth chart, and the evolution was also parallel to the P25 of the WHO chart (Fig. 2). The evolution of the median values of the z scores for weight-for-length and BMI-for-age were at -1 at birth and evolved to 0 after three months of intervention (at the mean age of 3.86 ± 0.82 months) (Fig. 3 and 4). The evolution of weight, length and head circumference was within the expected normal range and is listed in Table 8.

The number of defecations decreased from 22.1 dyring 1 month, over 17.4 during 2 months, to 14.0 during 3 months (Table 5). The number of "hard" defecations was very low as it varied between 2% and 3%.

Regurgitation occurred in 63% of all infants after one month being fed with the study formula, thus at a mean age of almost two months, decreasing to 41.6 % at the age of three months and 20% at the age of four months. Daily regurgitation decreased from 10.9% (1 month intervention) over 3.0% (2 months intervention) to 0.7% (3 months intervention). Only very few infants (~1%) regurgitated significant volumes (p < 0.001).

After one month intervention, 15.6% of the infants presented daily crying episodes, decreasing to 3.7 and 0.7 after 2 and 3 months intervention (all p < 0.001). Nighttime crying decreased from 38 to 4% during the three months intervention. The percent of infants with unsoothable crying after one month intervention (median age 1.89 month) was 26.3% of

 Table 5. Constipation Characteristics (Frequency, %) over Study Period

	After 1 month	After 2 months	After 3 months	<i>p</i> -value
Stool consistency				< 0.001
Liquid	68 (24.3)	25 (8.9)	6 (2.1)	
Creamy	166 (59.3)	199 (71.1)	193 (68.9)	
Jelly	37 (13.2)	51 (18.2)	75 (26.8)	
Hard	9 (3.2)	5 (1.8)	6 (2.1)	
Total	280 (100.0)	280 (100.0)	280 (100.0)	
Stool frequency	22.1±13.5	17.4 ± 10.0	14.0 ± 8.0	< 0.001

Values are presented as number (%) or mean±standard deviation.

Pediatr	Gastroenterol	Hepatol	Nutr
---------	---------------	---------	------

ansistency d ny										ALLEL 2 HIGHINS	emino	
	Rontamıl only	Mixed	Overall	<i>p</i> -value	Rontamil only	Mixed	Overall	<i>p</i> -value	Rontamil only	Mixed	Overall	<i>p</i> -value
				0.146				0.208				0.417
ny	58 (25.6)	10 (18.9)	68 (24.3)		22 (9.7)	3 (5.7)	25 (8.9)		6 (2.6)	(0) 0	6 (2.1)	
N	128 (56.4)		166 (59.3)		157 (69.2)	42 (79.2)	(1.1.) 199		154 (67.8)	39 (73.6)	193 (68.9)	
×	34 (15.0)		37 (13.2)		45 (19.8)	6 (11.3)	51 (18.2)		63 (27.8)	12 (22.6)	75 (26.8)	
Hard	7 (3.1)	2 (3.8)	9 (3.2)		3 (1.3)	2 (3.8)	5 (1.8)		4 (1.8)	2 (3.8)	6 (2.1)	
Total	227 (100.0)	53 (100.0)	280 (100.0)		227 (100.0)	53 (100.0)	280 (100.0)		227 (100.0)	53 (100.0)	280 (100.0)	
Regurgitation frequency				0.963				0.385				0.528
No	91 (40.1)	22 (41.5)	113 (40.4)		138 (60.8)	32 (60.4)	170 (60.7)		184 (81.1)	42 (79.2)	226 (80.7)	
<1/day	112 (49.3)	26 (49.1)	138 (49.3)		84 (37.0)	18 (34.0)	102 (36.4)		42 (18.5)	10 (18.9)	52 (18.6)	
Daily	24 (10.6)	5 (9.4)	29 (10.4)		5 (2.2)	3 (5.7)	8 (2.9)		1 (0.4)	1 (1.9)	2 (0.7)	
Total	227 (100.0)	53 (100.0)	280 (100.0)		227 (100.0)	53 (100.0)	280 (100.0)		227 (100.0)	53 (100.0)	280 (100.0)	
Regurgitation volume				0.568				0.778				0.670
No	98 (43.2)	25 (47.2)	123 (43.9)		143 (63.0)	33 (62.3)	176 (62.9)		185 (81.5)	41 (77.4)	226 (80.7)	
Insignificant	125 (55.1)		153 (54.6)		82 (36.1)	20 (37.7)	102 (36.4)		41 (18.1)	12 (22.6)	53 (18.9)	
Significant	4(1.8)	0 (0)	4 (1.4)		2 (0.9)	(0) 0	2 (0.7)		1 (0.4)	0 (0)	1 (0.4)	
	227 (100.0)	53 (100.0)	280 (100.0)		227 (100.0)	53 (100.0)	280 (100.0)		227 (100.0)	53 (100.0)	280 (100.0)	
Crying, unsoothable				0.262				0.806				>0.999
No	192 (84.6)	48 (90.6)	240 (85.7)		216 (95.2)	50 (94.3)	266 (95.0)		225 (99.1)	53 (100.0)	278 (99.3)	
Yes	35 (15.4)	5 (9.4)	40 (14.3)		11 (4.8)	3 (5.7)	14 (5.0)		2 (0.9)	0 (0)	2 (0.7)	
Total	227 (100.0)	53 (100.0)	280 (100.0)		227 (100.0)	53 (100.0)	280 (100.0)		227 (100.0)	53 (100.0)	280 (100.0)	
Crying, duration >3 h				0.039				0.232				
No	202 (89.0)	52 (98.1)	254 (90.7)		221 (97.4)	53 (100.0)	53 (100.0) 274 (97.9)		227 (100.0)	53 (100.0)	280 (100.0)	
Yes	25 (11.0)	1 (1.9)	26 (9.3)		6 (2.6)	(0) 0	6 (2.1)		0 (0)	0 (0)	0 (0)	
Total	227 (100.0)	53 (100.0)	$(100.0)\ 280\ (100.0)$		227 (100.0)	53 (100.0)	53 (100.0) 280 (100.0)		227 (100.0)	53 (100.0)	280 (100.0)	
Crying timing-day				0.134				0.213				>0.999
No	210 (92.5)	52 (98.1)	262 (93.6)		213 (93.8)	52 (98.1)	265 (94.6)		225 (99.1)	53 (100.0)	278 (99.3)	
Yes	17 (7.5)	1 (1.9)	18 (6.4)		14 (6.2)	1 (1.9)	15 (5.4)		2 (0.9)	0 (0)	2 (0.7)	
Total	227 (100.0)	53 (100.0)	280 (100.0)		227 (100.0)	53 (100.0)	(100.0) 280 (100.0)		227 (100.0)	53 (100.0)	280 (100.0)	
Crying timing-night				0.271				0.904				>0.999
No	163 (71.8)	42 (79.2)	205 (73.2)		190 (83.7)	44 (83.0)	234 (83.6)		218 (96.0)	51 (96.2)	269 (96.1)	
Yes	64 (28.2)	11 (20.8)	75 (26.8)		37 (16.3)	9 (17.0)	46 (16.4)		9 (4.0)	2 (3.8)	11 (3.9)	
Total	227 (100.0)	53 (100.0)	280 (100.0)		227 (100.0)	53 (100.0)	280 (100.0)		227 (100.0)	53 (100.0)	280 (100.0)	
Crying frequency-everyday				0.771				0.120				>0.999
No	189 (83.3)	45 (84.9)	234 (83.6)		217 (95.6)	53 (100.0)	(100.0) 270 (96.4)		225 (99.1)	53 (100.0)	278 (99.3)	
	38 (16.7)		46 (16.4)		(4.4)	0 (0)	10 (3.6)		2 (0.9)	0 (0)	2 (0.7)	
Total	227 (100.0)	53 (100.0)	280 (100.0)		227 (100.0)	53 (100.0)	280 (100.0)		227 (100.0)	53 (100.0)	280 (100.0)	
Crying frequency-occasionally				0.527				0.243				0.866
No	135 (59.5)	29 (54.7)	164 (58.6)		152 (67.0)	31 (58.5)	183 (65.4)		195 (85.9)	46(86.8)	241 (86.1)	
Yes	92 (40.5)	(45.3)	116 (41.4)		75 (33.0)	22 (41.5)	97 (34.6)		32 (14.1)	7 (13.2)	39 (13.9)	
Total	227 (100.0)	53 (100.0)	280 (100.0)		227 (100.0)	53 (100.0)	(100.0) 280 (100.0)		227 (100.0)	53 (100.0)	280 (100.0)	

Table 6. Constipation, Regurgitation and Crying over Study Period by Diet

172 Vol. 20, No. 3, September 2017

	Vacinal	Certean	Olicroin		lenimett	Gerran	Overall	enless 4	Indianal Viamia	Cereta	Otterall	2
	у аўшаі	CC301 C011	OVUIAII	<i>p</i> -value	v ağıılar		OVUIAII	<i>p</i> -value	v ağılıdı	CONTRAL		<u>م</u>
Stool consistency				0.627				0.150				
Liquid	42 (25.5)	26 (22.6)	68 (24.3)		14 (8.5)	11 (9.6)	25 (8.9)		5 (3.0)	1 (0.9)	6 (2.1)	
Creamy	95 (57.6)	71 (61.7)	166 (59.3)		112 (67.9)	87 (75.7) 199 (71.1)	199 (71.1)		111 (67.3)		193 (68.9)	
Jelly	24 (14.5)		37 (13.2)		37 (22.4)	14 (12.2)	51 (18.2)		46 (27.9)	(25.2)	75 (26.8)	
Hard	4 (2.4)	5 (4.3)	9 (3.2)		2 (1.2)	3 (2.6)	5 (1.8)		3 (1.8)	3 (2.6)	6 (2.1)	
Total	165 (100.0)	115 (100.0) 280 (100.0	280 (100.0)		165 (100.0)	115 (100.0) 280 (100.0)	280 (100.0)		165 (100.0)	115 (100.0)	(100.0) 280 (100.0)	
Regurgitation frequency				0.654				0.537				
No	66 (40.0)	47 (40.9)	113 (40.4)		97 (58.8)	73 (63.5)	170 (60.7)		136 (82.4)	90 (78.3)	226 (80.7)	
<1/day	84 (50.9)	54 (47.0)	138 (49.3)		62 (37.6)	40 (34.8) 102 (36.4)	102 (36.4)		29 (17.6)	23 (20.0)	52 (18.6)	
Daily	15 (9.1)	14 (12.2) 29 (10.4)	29 (10.4)		6 (3.6)	2 (1.7) 8 (2.9)	8 (2.9)		0 (0)	2 (1.7)	2 (0.7)	
Total	165 (100.0)	115 (100.0) 2	$(100.0)\ 280\ (100.0)$		165 (100.0)	115 (100.0) 280 (100.0)	280 (100.0)		165 (100.0)	115 (100.0)	280 (100.0)	
Regurgitation volume				0.285				0.946				
No	70 (42.4)	53 (46.1)	(46.1) 123 (43.9)		103 (62.4)	73 (63.5) 176 (62.9)	176 (62.9)		137 (83.0)	89 (77.4)	226 (80.7)	
Insignificant	94 (57.0)	59 (51.3) 153 (54.6)	153 (54.6)		61 (37.0)	41 (35.7)	102 (36.4)		27 (16.4)	26 (22.6)	53 (18.9)	
Significant	1 (0.6)	3 (2.6)	(2.6) 4 (1.4)		1 (0.6)	1 (0.9) 2 (0.7)	2 (0.7)		1 (0.6)	0 (0)	1 (0.4)	
Total	165 (100.0)	115 (100.0) 280 (100.0)	280 (100.0)		165 (100.0)	115 (100.0) 280 (100.0)	280 (100.0)		$165 \ (100.0)$	115 (100.0) 280 (100.0)	280 (100.0)	
Crying, unsoothable				0.882				0.676				Λ
No	141 (85.5)	99 (86.1) 240 (85.7)	240 (85.7)		156 (94.5)	110 (95.7) 266 (95.0)	266 (95.0)		164 (99.4)	114 (99.1)	278 (99.3)	
Yes	24 (14.5)	16 (13.9) 40 (14.3)	40 (14.3)		9 (5.5)	5 (4.3) 14 (5.0)	14 (5.0)		1 (0.6)	1 (0.9)	2 (0.7)	
Total	165 (100.0)	115 (100.0)	$(100.0)\ 280\ (100.0)$		165 (100.0)	115 (100.0) 280	280 (100.0)		$165 \ (100.0)$	115 (100.0) 280	280 (100.0)	
Crying, duration >3 h				0.331				0.697				
No	152 (92.1)	102 (88.7) 254 (90.7)	254 (90.7)		161 (97.6)	113 (98.3) 274 (97.9)	274 (97.9)		165 (100.0)	115 (100.0) 280 (100.0)	280 (100.0)	
Yes	13 (7.9)	13 (11.3) 26 (9.3)	26 (9.3)		4 (2.4)	2 (1.7) 6 (2.1)	6 (2.1)		0 (0)	0 (0)	0 (0)	
Total	165 (100.0)	115 (100.0) 280 (100.0)	280 (100.0)		$165 \ (100.0)$	115 (100.0) 280 (100.0)	280 (100.0)		165 (100.0)	115 (100.0) 280 (100.0)	280 (100.0)	
Crying timing-day				0.426				0.931				
No	156 (94.5)	106 (92.2) 262 (93.6)	262 (93.6)		156 (94.5)	109 (94.8) 265 (94.6)	265 (94.6)		163 (98.8)	115 (100.0) 278 (99.3)	278 (99.3)	
Yes	9 (5.5)	9 (7.8) 18 (6.4)	18 (6.4)		9 (5.5)	6 (5.2) 15 (5.4)	15 (5.4)		2 (1.2)	0 (0)	2 (0.7)	
Total	165 (100.0)	115 (100.0) 2	$(100.0)\ 280\ (100.0)$		165 (100.0)	115 (100.0) 280	280 (100.0)		$165 \ (100.0)$	115 (100.0) 280	280 (100.0)	
Crying timing-night				0.003				0.343				
No	110 (66.7)	95 (82.6) 205 (73.2)	205 (73.2)		135 (81.8)	99 (86.1) 234 (83.6)	234 (83.6)		159(96.4)		269 (96.1)	
Yes	55 (33.3)	20 (17.4) 75 (26.8)	75 (26.8)		30 (18.2)	16 (13.9) 46 (16.4)	46(16.4)		6 (3.6)	5 (4.3)	11 (3.9)	
Total	165 (100.0)	115 (100.0) 280 (100.0)	280 (100.0)		165 (100.0)	115 (100.0) 280 (100.0)	280 (100.0)		$165 \ (100.0)$	115 (100.0) 280 (100.0)	280 (100.0)	
Crying frequency-everyday				0.972				0.944				
No	138 (83.6)	96 (83.5) 234 (83.6)	234 (83.6)		159(96.4)	111 (96.5) 270 (96.4)	270 (96.4)		163 (98.8)	115 (100.0) 278 (99.3)	278 (99.3)	
Yes	27 (16.4)	19 (16.5)	46(16.4)		6 (3.6)	4 (3.5) 10 (3.6)	10 (3.6)		2 (1.2)	(0) 0	2 (0.7)	
Total	165 (100.0)	115 (100.0) 2	280 (100.0)		165 (100.0)	115 (100.0) 280 (100.0)	280 (100.0)		165 (100.0)	115 (100.0) 280 (100.0)	280 (100.0)	
Crying frequency-occasionally				0.059				0.639				
No	89 (53.9)	75 (65.2) 164 (58.6)	164 (58.6)			77 (67.0) 183 (65.4)	183 (65.4)		146 (88.5)	95 (82.6) 241 (86.1)	241 (86.1)	
Yes	76 (46.1)	40 (34.8) 116 (41.4)	116 (41.4)			38 (33.0)	97 (34.6)		19 (11.5)	20 (17.4) 39 (13.9)	39 (13.9)	
Total	165 (100.0)	115 (100.0) 280 (100.0)	280 (100.0)		165 (100.0)	115 (100.0)	280 (100.0)		165 (100.0)	115 (100.0)	280 (100.0)	I

Table 7. Constipation, Regurgitation and Crying over Study Period by Mode of Delivery

After 1 month

p-value 0.570

After 3 months

After 2 months

0.199

0.307

>0.999

www.pghn.org

Values are presented as number (%).

Yvan Vandenplas, et al : Synbiotic Formula

0.514

0.162

0.514

,

0.763

Pediatr Gastroenterol Hepatol Nutr




Fig. 1. Weight gain of the girls, plotted against the World Health Organization (WHO) growth charts.




Fig. 2. Weight gain of the boys, plotted against the World Health Organization (WHO) growth charts.

the babies that cried, but only 16% of the total number of infants with information available on crying incidence. After two and three months intervention, the incidence of unsoothable crying decreased to 5 and 0.01%, respectively (median postnatal age 3.89 and 4.89 months) (p < 0.001). The percent of infants that cried for three hours or more decreased from 10.5% after one month to 2.2% after two months. No infant cried during three hours or more after three months intervention (mean calendar age 4.89 months) (p < 0.001). No serious adverse event related to the study product was reported.






Fig. 3. Evolution of the weight-for-length z score.





DISCUSSION

The synbiotic formula was well tolerated by all infants, as the test formula was continued in all 280 infants for the three months study period. Overall satisfaction of the paediatricians was excellent, as they scored a median satisfaction of 9.3 on a 10 point Likert scale. For comparison, parents scored 9.0 in a trial with a new femented infant formula supple mented with prebiotics [12].

The primary outcome of the study was the demonstration of equivalence in infant weight gain per day during the intervention according to the WHO growth charts for exclusively breastfed infants. Weight gain was plotted against the WHO growth curves during the first six months of life; the first

Yvan Vandenplas, et al : Synbiotic Formula

	Birth	Entry	1 month	2 months	3 months
Weight (kg)	3.1 ± 0.4	3.7 ± 0.9	$4.6 {\pm} 0.9$	5.5 ± 0.9	6.3 ± 0.9
Length (cm)	50.1 ± 1.9	-	55.4±3.3	58.5 ± 3.5	61.5 ± 3.6
Head circumference (cm)	34.3 ± 1.4	-	37.3±1.9	38.9 ± 1.8	40.4 ± 1.8

Table 8. Weight, Length and Head Circumference Evolution over the Study Period

Values are presented as mean±standard deviation.

three months were with the study formula, from the age of 3-4 months up to the age of 6 months infants were fed a diferent starter formula. The curve for girls shows a median value just below the P50 at birth, with an evolution of the median value just below P50 up to the age of 6 months. The curve for boys, however, is different. The median birthweight for the boys was on the P25 of the WHO growth charts, indicating that these boys were relatively small-for-gestational age at birth. At the age of three months, the median weight of the bos is just below the P25 of the WHO-growth chart to end a 6 month just above the P25 WHO-growth chart. However, weight-for-length and BMI-for-age z score for the whole group were low (-1) at birth but evolved towards 0 during the three months study period, suggesting that physical growth and development with the study formula is within the norm.

The number of defecations decreased over the study period. With increasing age, infants produced fewer stools of greater firmness [13]. Infant and follow-on formulas containing *B. lactis* and galacto-oligoaccharides (GOS) and FOS were reported to be safe, without any additional benefit of the prebiotic over the probiotic [14]. A meta-analysis of seven different trials with infant formula supplemented with *B. lactis* results in growth similar to what is found in infants fed unsupplemented formula [9]. There is evidence that addition of prebiotics to infant formula alters the GI microbiota resembling that of breastfed infants [15]. Oligosaccharides are added to infant formula because of their presence in breast milk [15].

The Committee of Nutrition of the ESPGHAN reported that according to a systematic review of existing literature, the addicition of *B. lactis* to infant formula results in a reduction of 46% of the risk to develop acute gastroenteritis [11]. Infants consuming formula supplemented with B. lactis have an increased sIgA concentration in their stools [16]. Furthermore, cesarean-delivered infants consuming B. lactis had a better immune response, as evidenced by increased anti-rotavirus- and anti-poliovirus-specific IgA following immunization [16]. The results of the study by Holscher et al. [16] demonstrate that negative immune-related effects of not breastfeeding and cesarean delivery can be mitigated by including B. lactis in infant formula, thereby providing infants a safe, dietary, immune-modulating bacterial introduction. According to the results of one trial, the administration of Lactobacillus reuteri resulted in a decreased incidence of infant regurgitation, constipation and colic [17].

According to literature, the incidence of constipation is formula fed infants is 7.8% (P25-75: 3.8-15.0%) [18]. Only 3.2% of the infants fed with the new synbiotic formula were reported to have hard stools. Prebiotics are known to result in softer stools than unsupplemented formula, bringing the composition of stools of prebiotic infant formula closer to that of breastfed infants. This effect has been reported for infant formula supplementend with GOS and FOS [19], but also for low levels (0.24 g/100 mL) of GOS [20]. Infant formula supplemented with FOS (0.4 g/dL or 0.8 g/dL) or GOS/FOS (0.8 g/dL) were all reported to induce softer stools [21]. This study reports a similar effect with FOS on stool composition. sIgA in stools is increased in prebiotic supplemented infant formula compared to standard formula [22].

The incidence of infant regurgitation was reported to be 26.7% (P25-75: 14.9-40.9%) [17]. We report an incidence of only 10.9% of infants with daily regurPediatr Gastroenterol Hepatol Nutr

gitation, and only 1.6% in whom the volume was estimated as significant.

According to a review of existing literature, the mean prevalence of infantile crying and colic is 17.7% (P25-75: 10.5-21.0%) [18]. Iacono et al. [23] reported an incidence of 20.1% of infants with infantile colic. In this study with the synbiotic formula, the reported prevalence of crying was 15.6% at the age of two months, decreasing to 0.2% at four months of age. A GOS prebiotic-supplemented formula mimicked the effect of human milk in promoting Bifidobacterium and Lactobacillus growth and in inhibiting Clostridium growth, resulting in a significantly lower presence of colic [24]. The use of a partially hydrolysed formula supplemented with FOS and GOS was shown to induce a reduction of crying episodes in infants with colic after 7 and 14 days when compared with a standard formula [25]. We report a low incidence of crying and infantile colic with this new synbiotic formula compared to the reported prevalence in literature.

Interestingly, the administration of a probiotic mixture containing *L. acidophilus* DDS-1, *B. lactis* UABLA-12 and FOS was associated with significant clinical improvement in children with atopic dermatitis, with corresponding lymphocyte subset changes in peripheral blood [26]. The evaluation of the incidence and severity of atopic dermatitis with this new symbiotic formula compared to standard infant formula could be a topic for future research.

Since most studies suggest a trend for beneficial clinical effects, and since these ingredients are very safe, prebiotics added to infant formula bring infant formula one step closer to breastmilk, the golden standard [15].

ACKNOWLEDGEMENTS

This study has been supported by Rontis, providing free formula for the study period.

Yvan Vandenplas has participated as a clinical investigator, and/or advisory board member, and/or consultant, and/or speaker for Abbott Nutrition, Aspen, Biogaia, Biocodex, Danone, Hero, Kabrita, Nestle Nutrition Institute, Nutricia, Mead Johnson Nutrition, Merck, Olygose, Orafti, Phacobel, Rontis, Sari Husada, United Pharmaceuticals, Wyeth and Yakult. The co-authors did not report any postentioan COI.

REFERENCES

- 1. Field CJ. The immunological components of human milk and their effect on immune development in infants. J Nutr 2005;135:1-4.
- Garcia C, Duan RD, Brévaut-Malaty V, Gire C, Millet V, Simeoni U, et al. Bioactive compounds in human milk and intestinal health and maturity in preterm newborn: an overview. Cell Mol Biol (Noisy-le-grand) 2013; 59:108-31.
- 3. Jost T, Lacroix C, Braegger C, Chassard C. Impact of human milk bacteria and oligosaccharides on neonatal gut microbiota establishment and gut health. Nutr Rev 2015;73:426-37.
- 4. Wopereis H, Oozeer R, Knipping K, Belzer C, Knol J. The first thousand days-intestinal microbiology of early life: establishing a symbiosis. Pediatr Allergy Immunol 2014;25:428-38.
- Kapiki A, Costalos C, Oikonomidou C, Triantafyllidou A, Loukatou E, Pertrohilou V. The effect of a fructo-oligosaccharide supplemented formula on gut flora of preterm infants. Early Hum Dev 2007;83:335-9.
- Bäckhed F, Roswall J, Peng Y, Feng Q, Jia H, Kovatcheva-Datchary P, et al. Dynamics and stabilization of the human gut microbiome during the first year of life. Cell Host Microbe 2015;17:690-703.
- Reisinger KW, de Vaan L, Kramer BW, Wolfs TG, van Heurn LW, Derikx JP. Breast-feeding improves gut maturation compared with formula feeding in preterm babies. J Pediatr Gastroenterol Nutr 2014;59:720-4.
- 8. Vandenplas Y, Zakharova I, Dmitrieva Y. Oligosaccharides in infant formula: more evidence to validate the role of prebiotics. Br J Nutr 2015;113:1339-44.
- Szajewska H, Chmielewska A. Growth of infants fed formula supplemented with Bifidobacterium lactis Bb12 or Lactobacillus GG: a systematic review of randomized controlled trials. BMC Pediatr 2013;13:185.
- 10. Steenhout PG, Rochat F, Hager C. The effect of Bifidobacterium lactis on the growth of infants: a pooled analysis of randomized controlled studies. Ann Nutr Metab 2009;55:334-40.
- 11. Braegger C, Chmielewska A, Decsi T, Kolacek S, Mihatsch W, Moreno L, et al; ESPGHAN Committee on Nutrition. Supplementation of infant formula with pro-

biotics and/or prebiotics: a systematic review and comment by the ESPGHAN committee on nutrition. J Pediatr Gastroenterol Nutr 2011;52:238-50.

- Huet F, Abrahamse-Berkeveld M, Tims S, Simeoni U, Beley G, Savagner C, et al. Partly fermented infant formulae with specific oligosaccharides support adequate infant growth and are well-tolerated. J Pediatr Gastroenterol Nutr 2016;63:e43-53.
- Weaver LT, Ewing G, Taylor LC. The bowel habit of milk-fed infants. J Pediatr Gastroenterol Nutr 1988; 7:568-71.
- Bocquet A, Lachambre E, Kempf C, Beck L. Effect of infant and follow-on formulas containing B lactis and galacto- and fructo-oligosaccharides on infection in healthy term infants. J Pediatr Gastroenterol Nutr 2013; 57:180-7.
- 15. Vandenplas Y, De Greef E, Veereman G. Prebiotics in infant formula. Gut Microbes 2014;5:681-7.
- Holscher HD, Czerkies LA, Cekola P, Litov R, Benbow M, Santema S, et al. Bifidobacterium lactis Bb12 enhances intestinal antibody response in formula-fed infants: a randomized, double-blind, controlled trial. JPEN J Parenter Enteral Nutr 2012;36(1 Suppl): 106S-17S.
- Indrio F, Di Mauro A, Riezzo G, Civardi E, Intini C, Corvaglia L, et al. Prophylactic use of a probiotic in the prevention of colic, regurgitation, and functional constipation: a randomized clinical trial. JAMA Pediatr 2014;168:228-33.
- 18. Vandenplas Y, Abkari A, Bellaiche M, Benninga M, Chouraqui JP, Çokura F, et al. Prevalence and health outcomes of functional gastrointestinal symptoms in infants from birth to 12 months of age. J Pediatr Gastroenterol Nutr 2015;61:531-7.
- 19. Savino F, Maccario S, Castagno E, Cresi F, Cavallo F, Dalmasso P, et al. Advances in the management of di-

gestive problems during the first months of life. Acta Paediatr Suppl 2005;94:120-4.

- 20. Ben XM, Li J, Feng ZT, Shi SY, Lu YD, Chen R, et al. Low level of galacto-oligosaccharide in infant formula stimulates growth of intestinal Bifidobacteria and Lactobacilli. World J Gastroenterol 2008;14:6564-8.
- 21. Veereman-Wauters G, Staelens S, Van de Broek H, Plaskie K, Wesling F, Roger LC, et al. Physiological and bifidogenic effects of prebiotic supplements in infant formulae. J Pediatr Gastroenterol Nutr 2011;52:763-71.
- 22. Scholtens PA, Alliet P, Raes M, Alles MS, Kroes H, Boehm G, et al. Fecal secretory immunoglobulin A is increased in healthy infants who receive a formula with short-chain galacto-oligosaccharides and long-chain fructo-oligosaccharides. J Nutr 2008;138:1141-7.
- 23. Iacono G, Merolla R, D'Amico D, Bonci E, Cavataio F, Di Prima L, et al; Paediatric Study Group on Gastrointestinal Symptoms in Infancy. Gastrointestinal symptoms in infancy: a population-based prospective study. Dig Liver Dis 2005;37:432-8.
- 24. Giovannini M, Verduci E, Gregori D, Ballali S, Soldi S, Ghisleni D, et al; PLAGOS Trial Study Group. Prebiotic effect of an infant formula supplemented with galacto-oligosaccharides: randomized multicenter trial. J Am Coll Nutr 2014;33:385-93.
- 25. Savino F, Palumeri E, Castagno E, Cresi F, Dalmasso P, Cavallo F, et al. Reduction of crying episodes owing to infantile colic: a randomized controlled study on the efficacy of a new infant formula. Eur J Clin Nutr 2006;60:1304-10.
- Gerasimov SV, Vasjuta VV, Myhovych OO, Bondarchuk LI. Probiotic supplement reduces atopic dermatitis in preschool children: a randomized, double-blind, placebo-controlled, clinical trial. Am J Clin Dermatol 2010;11:351-61.